EP3920919A4 - Verfahren und zusammensetzungen zur modulierung der spleissung - Google Patents
Verfahren und zusammensetzungen zur modulierung der spleissung Download PDFInfo
- Publication number
- EP3920919A4 EP3920919A4 EP20753044.5A EP20753044A EP3920919A4 EP 3920919 A4 EP3920919 A4 EP 3920919A4 EP 20753044 A EP20753044 A EP 20753044A EP 3920919 A4 EP3920919 A4 EP 3920919A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- modulating splicing
- splicing
- modulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962801506P | 2019-02-05 | 2019-02-05 | |
US201962801486P | 2019-02-05 | 2019-02-05 | |
US201962801502P | 2019-02-05 | 2019-02-05 | |
PCT/US2020/016671 WO2020163401A1 (en) | 2019-02-05 | 2020-02-04 | Methods and compositions for modulating splicing |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3920919A1 EP3920919A1 (de) | 2021-12-15 |
EP3920919A4 true EP3920919A4 (de) | 2023-03-29 |
Family
ID=71947086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20753044.5A Withdrawn EP3920919A4 (de) | 2019-02-05 | 2020-02-04 | Verfahren und zusammensetzungen zur modulierung der spleissung |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3920919A4 (de) |
JP (1) | JP2022519312A (de) |
KR (1) | KR20210134657A (de) |
CN (1) | CN113645970A (de) |
WO (1) | WO2020163401A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102650496B1 (ko) | 2018-10-31 | 2024-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물 |
CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
JP2022521467A (ja) | 2019-02-05 | 2022-04-08 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
JP2022519323A (ja) | 2019-02-06 | 2022-03-22 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
CN114650822A (zh) | 2019-11-01 | 2022-06-21 | 诺华股份有限公司 | 剪接调节子用于减慢亨廷顿氏病进展的治疗的用途 |
JP2023532623A (ja) | 2020-05-13 | 2023-07-31 | シーエイチディーアイ ファウンデーション,インコーポレーテッド | ハンチントン病を処置するためのhttモジュレータ |
WO2022060944A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137030A2 (en) * | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
WO2011095625A1 (en) * | 2010-02-05 | 2011-08-11 | Heptares Therapeutics Limited | 1,2,4-triazine-4-amine derivatives |
WO2017100726A1 (en) * | 2015-12-10 | 2017-06-15 | Ptc Therapeutics, Inc. | Methods for treatng huntington's disease |
WO2018232039A1 (en) * | 2017-06-14 | 2018-12-20 | Ptc Therapeutics, Inc. | Methods for modifying rna splicing |
WO2019028440A1 (en) * | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
WO2020163248A1 (en) * | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
WO2020163382A1 (en) * | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107428729B (zh) * | 2015-02-09 | 2021-07-16 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的化合物 |
CN112272666A (zh) * | 2018-04-10 | 2021-01-26 | 斯基霍克疗法公司 | 用于治疗癌症的化合物 |
-
2020
- 2020-02-04 WO PCT/US2020/016671 patent/WO2020163401A1/en unknown
- 2020-02-04 KR KR1020217028354A patent/KR20210134657A/ko unknown
- 2020-02-04 CN CN202080026920.4A patent/CN113645970A/zh active Pending
- 2020-02-04 EP EP20753044.5A patent/EP3920919A4/de not_active Withdrawn
- 2020-02-04 JP JP2021545875A patent/JP2022519312A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137030A2 (en) * | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
WO2011095625A1 (en) * | 2010-02-05 | 2011-08-11 | Heptares Therapeutics Limited | 1,2,4-triazine-4-amine derivatives |
WO2017100726A1 (en) * | 2015-12-10 | 2017-06-15 | Ptc Therapeutics, Inc. | Methods for treatng huntington's disease |
WO2018232039A1 (en) * | 2017-06-14 | 2018-12-20 | Ptc Therapeutics, Inc. | Methods for modifying rna splicing |
WO2019028440A1 (en) * | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
WO2020163248A1 (en) * | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
WO2020163382A1 (en) * | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
Non-Patent Citations (1)
Title |
---|
See also references of WO2020163401A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP3920919A1 (de) | 2021-12-15 |
CN113645970A (zh) | 2021-11-12 |
WO2020163401A1 (en) | 2020-08-13 |
JP2022519312A (ja) | 2022-03-22 |
KR20210134657A (ko) | 2021-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3920918A4 (de) | Verfahren und zusammensetzungen zur modulierung von spleissung | |
EP3920917A4 (de) | Verfahren und zusammensetzungen zur modulierung der spleissung | |
EP3661509A4 (de) | Verfahren und zusammensetzungen zur modulierung der spleissung | |
EP3920915A4 (de) | Verfahren und zusammensetzungen zur modulierung der spleissung | |
EP3920928A4 (de) | Verfahren und zusammensetzungen zur modulierung von spleissung | |
EP3920919A4 (de) | Verfahren und zusammensetzungen zur modulierung der spleissung | |
EP3920916A4 (de) | Verfahren und zusammensetzungen zur modulierung der spleissung | |
EP3920920A4 (de) | Verfahren und zusammensetzungen zur modulierung von spleissung | |
EP3958970A4 (de) | Verfahren und zusammensetzungen zum modulieren von spleissen und translation | |
EP3921311A4 (de) | Verfahren und zusammensetzungen zur spleissungsmodulierung | |
IL290595A (en) | Compositions and methods for modulating protein fusion and expression | |
EP3920926A4 (de) | Verfahren und zusammensetzungen zur modulierung der spleissung | |
EP3920910A4 (de) | Verfahren und zusammensetzungen zur modulierung der spleissung | |
EP3938352A4 (de) | Verfahren und zusammensetzungen zur spleissungsmodulierung | |
EP3870173A4 (de) | Wdr5-inhibitoren und modulatoren | |
EP3585171A4 (de) | Zusammensetzungen und verwandte verfahren zur modulation von endosymbionten | |
EP3911682A4 (de) | Zusammensetzungen und verfahren zur modulation der zellulären internalisierung | |
EP3947684A4 (de) | Verbindungen und verfahren zur modulation von ube3a-ats | |
EP3870206A4 (de) | Zusammensetzungen und verfahren zur modulation der faktor-viii-funktion | |
EP3927327A4 (de) | Verfahren und vorrichtungen zur lokalisierung von zusammensetzungen | |
EP3849564A4 (de) | Verbindungen und verfahren zur modulation der cln3-expression | |
EP3924762A4 (de) | Spleissverschluss | |
EP3976026A4 (de) | Zusammensetzungen und verfahren zur modulation des kognitiven verhaltens | |
EP4031155A4 (de) | Zusammensetzungen und verfahren zur mikrobiommodulation | |
EP3956450A4 (de) | Verbindungen und verfahren zur modulation von gfap |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210824 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230223 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/00 20060101ALI20230217BHEP Ipc: A61K 31/53 20060101ALI20230217BHEP Ipc: A61K 31/46 20060101ALI20230217BHEP Ipc: A61K 31/439 20060101AFI20230217BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230901 |